SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Karlsson Mats O)
 

Sökning: WFRF:(Karlsson Mats O) > Randomized exposure...

Randomized exposure-controlled trials : Impact of randomization and analysis strategies

Karlsson, Kristin E. (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Grahnén, Anders (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Karlsson, Mats O. (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
visa fler...
Jonsson, E. Niclas (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
visa färre...
 (creator_code:org_t)
Wiley, 2007
2007
Engelska.
Ingår i: British Journal of Clinical Pharmacology. - : Wiley. - 0306-5251 .- 1365-2125. ; 64:3, s. 266-277
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims: In the literature, five potential benefits of randomizing clinical trials on concentration levels, rather than dose, have been proposed: (i) statistical study power will increase; (ii) study power will be less sensitive to high variability in the pharmacokinetics (PK); (iii) the power of establishing an exposure-response relationship will be robust to correlations between PK and pharmacodynamics (PD); (iv) estimates of the exposure-response relationship are likely to be less biased; and (v) studies will provide a better control of exposure in situations with toxicity issues. The main aim of this study was to investigate if these five statements are valid when the trial results are evaluated using a model-based analysis. Methods: Quantitative relationships between drug dose, concentration, biomarker and clinical end-point were defined using pharmacometric models. Three randomization schemes for exposure-controlled trials, dose-controlled (RDCT), concentration-controlled (RCCT) and biomarker-controlled (RBCT), were simulated and analysed according to the models. Results: (i) The RCCT and RBCT had lower statistical power than RDCT in a model-based analysis; (ii) with a model-based analysis the power for an RDCT increased with increasing PK variability; (iii) the statistical power in a model-based analysis was robust to correlations between CL and EC 50 or Emax; (iv) under all conditions the bias was negligible (<3%); and (v) for studies with equal power RCCT could produce either more or fewer adverse events compared with an RDCT. Conclusion: Alternative randomization schemes may not have the proposed advantages if a model-based analysis is employed.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

Clinical trial simulation
Model-based analysis
Pharmacometrics
Randomized concentration-controlled trial
Randomized dose-controlled trial
Study design
PHARMACY
FARMACI

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy